Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SQZ Biotechnologies : to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting

10/04/2021 | 06:46am EST

Posters Detail Preclinical Data on SQZ AAC and eAPC Platforms and Enhanced Tumor Infiltrating Lymphocytes

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. The data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

“We are excited to share new preclinical data on our AAC and eAPC platforms, as well as initial data on the engineering of tumor infiltrating lymphocytes,” said Armon Sharei, Ph.D., Chief Executive Officer at SQZ Biotechnologies. “These data further highlight our potential to create multiple cell therapies leveraging diverse biology to combat cancer.”


Title: RBC-Derived, Activating Antigen Carriers (SQZ™ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo
Presenter: Katarina Blagovic, PhD
Abstract Number: 156

Title: Generating Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic Cell Squeezing
Presenter: Devin Bridgen, PhD
Abstract Number: 165

Title: SQZ™ eAPCs Generated from PBMCs by Delivery of Multiple mRNAs Encoding for Antigens, Costimulatory Proteins, and Engineered Cytokines
Presenter: Michael F. Maloney, PhD
Abstract Number: 211

Full text of the abstracts will be available on the SITC website at 8:00 a.m. ET on Tuesday, November 9, and posters will be available on the company’s website at 7:00 a.m. ET on November 12. Live poster presentations will be on November 12 and 13 from 7:00 a.m. - 8:30 p.m. ET.

About SQZ Biotechnologies

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to our platform development, manufacturing capabilities, product candidates, preclinical and clinical activities and outcomes, development plans and progress, clinical efficacy, therapeutic impact and market opportunities. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of this date and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this press release, we have not independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

ę Business Wire 2021
11/18SQZ BIOTECHNOLOGIES : Amendment to Current Report (Form 8-K/A)
11/18SQZ BIOTECHNOLOGIES CO Change in Directors or Principal Officers (form 8-K/A)
11/15SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference
11/12SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor I..
11/12SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor I..
11/10SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio U..
11/10SQZ BIOTECHNOLOGIES CO Management's Discussion and Analysis of Financial Condition and..
11/10SQZ Biotechnologies Company Reports Earnings Results for the Third Quarter and Nine Mon..
11/04SQZ BIOTECHNOLOGIES CO : Change in Directors or Principal Officers (form 8-K)
11/04SQZ Biotechnologies Company Announces Resignation of Teri Loxam as Chief Financial Offi..
More news
Analyst Recommendations on SQZ BIOTECHNOLOGIES COMPANY
More recommendations
Financials (USD)
Sales 2021 22,5 M - -
Net income 2021 -77,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,44x
Yield 2021 -
Capitalization 345 M 345 M -
Capi. / Sales 2021 15,3x
Capi. / Sales 2022 10,7x
Nbr of Employees 98
Free-Float 94,7%
Duration : Period :
SQZ Biotechnologies Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SQZ BIOTECHNOLOGIES COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 12,28 $
Average target price 36,25 $
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Armon Sharei President, CEO, CFO & Director
Amy L. Schulman Chairman
Howard Bernstein Chief Scientific Officer
Klavis F. Jensen Independent Director
Marc W. Elia Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431